It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Verdiva launched with $411 million. Indian drugmaker Anthem Biosciences filed for an IPO worth $397 million. Tenvie Therapeutics emerged with $200 million. Maze Therapeutics files for $115 million ...

Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

NASDAQ:DNLI opened at $21.25 on Friday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The company has a fifty day moving average price of $24.23 and a 200 ...

KNOXVILLE, Tenn. (WATE) — The Knox County Highway Department covers nearly 2,000 miles of roadway, excluding state routes like Chapman Highway or the surrounding interstates. The process to get ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of small ...

NEW YORK, NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account ...